 "Panacea Biotec zooms 18% on USFDA approval for migraine drug")
Panacea Biotec has zoomed 18% to Rs 149, also its 52-week high on the National Stock Exchange (NSE) in noon deal after the pharmaceutical company announced that it has receive the US regulator’s approval for making a migraine drug.
“The US Food and Drug Administration (USFDA) has granted approval for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate tablet, orally disintegrating 5 mg and 10 mg,” Panacea Biotec said in a release.
Rizatriptan Benzoate is a serotonin (5-HT) 1B/1D receptor against (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients.
This generic is equivalent to MAXALT-MLT ODT of Merck & Co. The current annual sales for Rizatriptan Benzoate tablet, orally disintegrating 5 mg and 10 mg in the US market is approximately $ 60 million, it added.
The company plans to launch the product within first quarter of 2017 through its distribution partner in US.
Panacea Biotec recently got approval of its anti-cancer formulation facility from USFDA in November, 2016.
At 01:56 pm; the stock was up 15% at Rs 146 on the NSE on back of heavy volumes. A combined 1.72 million shares changed hands on the counter on the NSE and BSE so far.
“The US Food and Drug Administration (USFDA) has granted approval for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate tablet, orally disintegrating 5 mg and 10 mg,” Panacea Biotec said in a release.
Rizatriptan Benzoate is a serotonin (5-HT) 1B/1D receptor against (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients.
This generic is equivalent to MAXALT-MLT ODT of Merck & Co. The current annual sales for Rizatriptan Benzoate tablet, orally disintegrating 5 mg and 10 mg in the US market is approximately $ 60 million, it added.
The company plans to launch the product within first quarter of 2017 through its distribution partner in US.
Panacea Biotec recently got approval of its anti-cancer formulation facility from USFDA in November, 2016.
At 01:56 pm; the stock was up 15% at Rs 146 on the NSE on back of heavy volumes. A combined 1.72 million shares changed hands on the counter on the NSE and BSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%